Software and services for clinical research
Location: United States, Wisconsin, Madison
Investors 2
| Date | Name | Website |
| - | Primus Cap... | primuscapi... |
| - | Silicon Pa... | siliconpas... |
Mentions in press and media 6
| Date | Title | Description |
| 05.09.2019 | Advarra Announces Intent to Acquire Forte, Market-Leading Provider of Clinical Technology Solutions | The move strengthens the site-centric solutions portfolio of the largest global research compliance services organization COLUMBIA, Md. and MADISON, Wis., September 5, 2019—Advarra, the premier provider of institutional review board (IRB),... |
| 21.09.2018 | How one pharmaceutical company is reinventing the clinical trial | Millions of Americans— most of us, in fact — rely on medications, from prescription drugs for high cholesterol, diabetes, asthma, cancer, and the like to over-the-counter medicines for allergy, acne, and other conditions. While the myriad m... |
| 13.08.2015 | Wisconsin Roundup: Johnson Controls, BrightStar, Orbitec, & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Here are some of the past week’s major headlines from Wisconsin’s tech and innovation community: —The BrightStar Wisconsin Foundation announced investments in five companies a... |
| 01.05.2015 | Forte Research Systems Secures Growth Investment from Primus Capital | Forte Research Systems, Inc., a Madison, Wisconsin-based developer of specialized clinical research management software, secured a growth investment from Primus Capital. The amount of the transaction was not disclosed. In conjunction with t... |
| 20.12.2006 | Forte Design Systems raises $5.4M for hardware chip design | Forte Design Systems, a San Jose company that helps create chip hardware designs, said it has raised $5.4 million in a fourth round of venture backing. Saints Capital joined 3i Corporation and Infinity Capital as main investors in the compa... |
| - | Virtual clinical trials now being used to fast-track drug development during coronavirus crisis | The average cost of bringing a new drug to market has been estimated to be as high as $2.6 billion, with two-thirds of the cost going to clinical trials — about 90% of which end in failure. Eager to streamline the process during the pandemi... |